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Abstract 
A single tool for early detection, accurate staging, and personalized treatment of prostate cancer 
(PCa) would be a major breakthrough in the field of PCa. Gastrin-releasing peptide receptor 
(GRPR) targeting peptides are promising probes for a theranostic approach for PCa overex-
pressing GRPR. However, the successful application of small peptides in a theranostic approach is 
often hampered by their fast in vivo degradation by proteolytic enzymes, such as neutral endo-
peptidase (NEP). Here we show for the first time that co-injection of a NEP inhibitor (phospho-
ramidon (PA)) can lead to an impressive enhancement of diagnostic sensitivity and therapeutic 
efficacy of the theranostic 68Ga-/177Lu-JMV4168 GRPR-antagonist. Co-injection of PA (300 µg) led 
to stabilization of 177Lu-JMV4168 in murine peripheral blood. In PC-3 tumor-bearing mice, PA 
co-injection led to a two-fold increase in tumor uptake of 68Ga-/177Lu-JMV4168, 1 h after injection. 
In positron emission tomography (PET) imaging with 68Ga-JMV4168, PA co-injection substantially 
enhanced PC-3 tumor signal intensity. Radionuclide therapy with 177Lu-JMV4168 resulted in sig-
nificant regression of PC-3 tumor size. Radionuclide therapy efficacy was confirmed by production 
of DNA double strand breaks, decreased cell proliferation and increased apoptosis. Increased 
survival rates were observed in mice treated with 177Lu-JMV4168 plus PA as compared to those 
without PA. This data shows that co-injection of the enzyme inhibitor PA greatly enhances the 
theranostic potential of GRPR-radioantagonists for future application in PCa patients. 
Key words: GRPR; neutral endopeptidase; enzyme inhibition; phosphoramidon; theranostics; PET imaging; 
radionuclide therapy, prostate cancer. 
Introduction 
Prostate cancer (PCa) is the most frequently di-
agnosed cancer and the second leading cause of can-
cer-related death among men in the United States [1]. 
The five-year relative survival rate for localized and 
regional PCa is 100%, but decreases to 29% when the 
cancer has spread to distant sites [2]. Prognosis and 
treatment options are strongly related to disease stage 
and grade at time of diagnosis. Early diagnosed and 
locally confined tumors can be treated by radical 
prostatectomy and/or local radiation therapy, 
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whereas for advanced, disseminated PCa curative 
treatment is not available [2]. This underlines the 
importance of early detection and accurate staging for 
the successful management of PCa patients.  
Currently, local staging is mostly based on ul-
trasound, biopsies and level of serum prostate-specific 
antigen. Recent advances in molecular imaging tech-
niques have highlighted the potential of PET imaging, 
providing a sensitive and non-invasive detection 
method for PCa lesions. Metabolic PET radiotracers, 
such as 18F-fluoro-2-deoxy-D-glucose (FDG) or 
18F-fluoro-choline have been used to detect recurrent 
metastatic PCa with high metabolic rates, but are 
suboptimal for the detection of slow-growing primary 
tumors. 
An alternative strategy focuses on the develop-
ment of receptor-directed PET imaging agents. PET 
radiotracers targeting prostate-specific membrane 
antigen (PSMA) and gastrin-releasing peptide recep-
tor (GRPR) have shown promising results for detec-
tion of primary and metastasized PCa in early clinical 
studies [3-6]. Besides their use for diagnostic imaging, 
these targeting agents may also be used as therapeutic 
agents for tumor-targeted radionuclide therapy of 
PCa. PSMA-targeted agents labeled with the 
β-emitting radioisotope 177Lu are currently evaluated 
in clinical studies [7, 8]. The powerful combination of 
diagnosis and therapy by one single probe in a 
“theranostic” strategy could effectively contribute to a 
more personalized management of PCa patients, 
whereby imaging can guide the choice of the most 
suitable therapeutic option for each patient.  
The aim of the present study was to develop a 
theranostic agent based on a GRPR-antagonist with 
application prospects in the personalized treatment of 
PCa patients.  
GRPRs are overexpressed in the majority of 
primary prostate tumors and in a subset of patients 
with lymph node and/or bone metastasis [9, 10], 
making it an interesting target for radionuclide ther-
apy. GRPR-antagonists are promising molecular 
probes, owing to their superior tumor-targeting and 
pharmacokinetic properties compared to agonists 
[11]. GRPR agonists were also shown to induce side 
effects in patients, owing to their physiological activ-
ity [12, 13]. The potential of the 68Ga-labeled 
GRPR-antagonist, JMV4168, for PET imaging of 
prostate cancer was reported previously in preclinical 
studies [14].  
However, delivery of radiopeptides to the tumor 
will be challenged by the action of proteolytic en-
zymes present in blood, vasculature walls, liver, 
lungs, kidneys and gastrointestinal tract. In vivo deg-
radation of radiopeptides by proteolytic enzymes may 
hamper their targeting properties, thereby limiting 
their successful application as theranostic probes. One 
of the key proteolytic enzymes is neutral endopepti-
dase 24.11 (NEP, EC 3.4.24.11, neprilysin, CD10, 
MME), a cell surface metallopeptidase responsible for 
catalytic inactivation of many neuropeptide sub-
strates, including bombesin-like peptides [15-17]. NEP 
is abundantly expressed in the human body, includ-
ing vasculature walls, major organs and tissues, po-
tentially hampering radiopeptide-based imaging and 
therapy by cleaving radiopeptides on the amino side 
of hydrophobic amino acids. The released inactive 
radiometabolites will not be able to interact with the 
tumor-associated target-receptors, and as a result, 
diagnostic sensitivity and therapeutic efficacy will be 
severely compromised. In previous studies we have 
shown that co-injection of a single enzyme inhibitor, 
phosphoramidon (PA), could stabilize radiopeptides 
in vivo by inhibition of NEP. This strategy led to no-
table enhancement of tumor uptake of radiopeptides, 
whereas uptake in most non-target healthy tissues 
was not affected [18]. We hypothesize that this strat-
egy would be particularly interesting to enhance the 
therapeutic efficacy of radionuclide therapy as well, 
by delivering a higher cytotoxic radiation dose to 
cancer cells at similar dose exposure of healthy tis-
sues.  
The aim of this study was to investigate the effect 
of in vivo stabilization by PA on diagnostic sensitivity 
and therapeutic efficacy of the GRPR-targeted 
theranostic agent 68Ga/177Lu-JMV4168 in nude mice 
with subcutaneous (sc) human prostate tumors. 
Materials and Methods 
Peptide, reagents, cell line and mice 
JMV4168 (DOTA-βAla-βAla-[H-D-Phe-Gln-Trp- 
Ala-Val-Gly-His-Sta-Leu-NH2], Figure 1) was synthe-
sized as described previously [19]. Chemicals were 
purchased from Sigma-Aldrich, unless otherwise 
stated. Phosphoramidon (PA) was purchased from 
Peptides International Inc. 177LuCl3 was purchased 
from IDB Holland and no-carrier added (n.c.a.) ItG 
177LuCl3 was obtained from ITG Isotope Technologies 
Garching GmbH. 175Lu was obtained from Merck as 1 
g/L standard solution in nitric acid. The human PCa 
cell line PC-3 was obtained from the American Type 
Culture Collection (CRL 1435) and cell culture rea-
gents from Life Technologies. Cells were cultured in 
Ham’s F-12K (Kaighn’s) Medium supplemented with 
10% fetal bovine serum, penicillin (100 units/mL), 
and streptomycin (100 µg/mL). Cells were grown in 
tissue culture flasks at 37°C in a humidified atmos-
phere containing 5% CO2. Male nude BALB/c mice (8 
weeks old) were obtained from Janvier. All animal 
experiments were approved by the Animal Experi-
 Theranostics 2016, Vol. 6, Issue 1 
 
http://www.thno.org 
106 
ments Committee under the Dutch Experiments on 
Animal Act and adhered to the European Convention 
for Protection of Vertebrate Animals used for Exper-
imental Purposes (Directive 86/609/EEC).  
Labeling of JMV4168 with 68Ga, 177Lu and 175Lu 
Elution of 68Ga from a 68Ga/68Ge generator 
(IGG-100, Eckert & Ziegler AG) was performed using 
fractionated elution with 0.1 M HCl (Rotem Industries 
Ltd). For PET imaging and biodistribution studies, 
JMV4168 (1-2 nmol) was mixed with 68Ga eluate (200 
µL), sodium acetate (0.5 M, 50 µL) and ethanol (30 µL). 
The reaction mixture was heated for 10 min at 95°C. 
After reaction, ethylenediaminetetraacetic acid 
(EDTA, 4 mM) was added to complex free 68Ga, and 
the reaction mixture was filtered (0.02 µm What-
manTM filter, GE Healthcare) to remove 
68Ga-hydroxides [20].  
JMV4168 was labeled with carrier-added 
177LuCl3 (IDB Holland) with a specific activity (ratio 
between amount of bound radioactivity and total 
molar quantity of peptide) of 125 MBq/nmol for in 
vivo stability studies and 60 MBq/nmol for biodistri-
bution studies. Labeling was performed in 20 mM 
sodium acetate, for 15 min at 80°C. Radioprotectants 
(gentisic acid, ascorbic acid and methionine, 3.5 mM) 
were added to prevent radiolysis.  
To obtain higher specific activity (i.e. 250 
MBq/nmol) for in vivo therapy studies, JMV4168 was 
labeled with n.c.a. 177LuCl3 (ITG Munich) as the 
presence of 176Lu in carrier-added 177LuCl3 limits the 
maximum achievable specific activity to 125 
MBq/nmol. Labeling was performed in 50 mM so-
dium acetate for 15 min at 80°C with radioprotectants. 
An excess of diethylenetriaminepentaacetic acid 
(DTPA, 4 mM) was added to complex free 177LuCl3 
after reaction.  
For control experiments, JMV4168 was labeled 
with the stable isotope 175Lu. JMV4168 was incubated 
with a 2-fold molar excess 175Lu in 80 mM sodium 
acetate, for 15 min at 80°C.  
Vehicle for animal injection 
To allow for injection into mice, the radiolabeled 
peptide was diluted in a vehicle. For biodistribution 
studies, vehicle consisted of 5% (v/v) ethanol, 0.05% 
(w/v) bovine serum albumin (BSA) in phos-
phate-buffered saline (PBS), pH 7.4, containing a 
mixture of 0.5 mM radioprotectants. For therapy 
studies with higher activity concentration, vehicle 
consisted of 5% (v/v) ethanol, 0.05% (w/v) BSA in 
PBS, pH 7.4, containing 5 mM radioprotectants.  
Quality control 
Labeling efficiency was assessed by instant thin 
layer chromatography (iTLC) using silica gel coated 
paper (Varian Medical Systems, Inc.) and 0.1 M citrate 
buffer pH 5 as eluent. Colloid formation was deter-
mined by iTLC using silica gel-coated paper and 1 M 
NH4OAc:methanol (1:3) as eluent. Radiochemical 
purity of labeled peptides was analyzed by RP-HPLC 
on a Breeze system (Waters). A C-18 column (Sym-
metry Shield, 4.6 mm x 250 mm; particle size 5 μm, 
Waters) was used at a flow rate of 1 mL/min with the 
following buffer system: buffer A, 0.1% v/v tri-
fluoroacetic acid in water; buffer B, methanol; with a 
gradient as follows: 100% buffer A (0-5 min), 60% 
buffer B (5-5.01 min), 80% buffer B (5.01-20 min), 100% 
buffer B (20.01-25 min), 100% buffer A (25.01-30 min). 
The radioactivity of the eluate was monitored using 
an in-line NaI radiodetector, digital multichannel an-
alyzer and dedicated software (MetorX B.V.). Elution 
profiles were analyzed using Empower 3 software 
(Waters).  
In vivo stability studies 
Non-tumor bearing mice were injected intraper-
itoneally (ip) with 177Lu-JMV4168 (25 MBq, 200 pmol) 
in vehicle, or in vehicle containing PA (300 μg). Blood 
was drawn 15 min after injection and collected in a 
polypropylene tube coated with EDTA containing PA 
(30 μg), and 50 nmol of radioprotectants on ice. Plas-
ma proteins were precipitated by adding 50% ethanol, 
centrifuged for 10 min at 4°C and the extract was an-
alyzed by radio-HPLC. HPLC fractions were collected 
every minute and counted in a γ-counter to quantify 
intact radiopeptide and degradation products.  
 
 
Figure 1. Chemical structure of JMV4168 (DOTA-βAla-βAla-[H-D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2]) 
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Prostate cancer xenograft model 
Mice were injected subcutaneously on the right 
shoulder with a PC-3 cell suspension (3 x 106 cells, 200 
µL, 67% RPMI, 33% Matrigel [BD Bioscience]). Three 
to four weeks after inoculation, tumor size averaged 
200 mm3 and mice were used for biodistribution, PET 
imaging and therapy studies. 
Biodistribution studies 
68Ga-JMV4168 (1 MBq, 200 pmol) was injected 
intravenously (iv) with vehicle (control) or with PA 
(300 µg) in vehicle. Mice were euthanized 1 h or 2 h 
after injection. 177Lu-JMV4168 (0.7 MBq, 200 pmol) 
was injected iv or ip with or without PA (300 µg) in 
vehicle. Mice were sacrificed at 1 h, 4 h or 24 h after 
injection for 177Lu-JMV4168 in controls, and 1 h or 4 h 
for 177Lu-JMV4168 with PA. Blood, tumor, and rele-
vant organs and tissues were collected, weighed and 
counted in a γ-counter (WIZARD, PerkinElmer) with 
a counting time of 60 sec per sample, isotope-specific 
energy window and an error not exceeding 5%. The 
percentage of the injected dose per gram (%ID/g) was 
determined for each tissue sample.  
Dosimetry 
Biodistribution data of 177Lu-JMV4168 in controls 
(iv and ip) were used to estimate the absorbed radia-
tion doses to the organs with physiological uptake 
and tumor. A single-exponential expression was fitted 
to the activity data at 1, 4 and 24 h, and the cumulative 
activity concentration in each organ was calculated by 
analytic integration of the fitted expression. Absorbed 
radiation doses of 177Lu-JMV4168 with PA were esti-
mated assuming equivalent clearance as without PA 
from 4 to 24 h.  
Absorbed radiation doses to the organs were es-
timated according to the MIRD-scheme [21] with the 
following equation: 𝐷𝐷(𝑟𝑟𝑇𝑇) = ∑ Ã(𝑟𝑟𝑆𝑆) × 𝑆𝑆(𝑟𝑟𝑇𝑇 ← 𝑟𝑟𝑆𝑆)𝑟𝑟𝑆𝑆 , 
with 𝐷𝐷(𝑟𝑟𝑇𝑇) the absorbed dose to a target organ 𝑟𝑟𝑇𝑇 , Ã(𝑟𝑟𝑆𝑆) the time-integrated activity in a source organ 𝑟𝑟𝑆𝑆 
and 𝑆𝑆(𝑟𝑟𝑇𝑇 ← 𝑟𝑟𝑆𝑆) the absorbed dose rate per unit activity 
of 177Lu. The S-values were obtained for a standard-
ized 25 g mouse from the RADAR realistic animal 
models [22]. The biodistribution data are measured in 
activity concentration and hence the time-integrated 
activity concentration is obtained and this is multi-
plied with the source organ mass, as used in the 
phantom for the S-value calculation.  
The Linear Quadratic (LQ) model was used to 
predict cell survival for PC-3 radiation response (α = 
0.13 /Gy, β = 0.024 /Gy2, doubling time of 11 days, 
sub-lethal repair half-life Tµ = 1 h, clonogenic cell 
density; 107/g) [23]. Radiation sensitivity was esti-
mated by external 137Cs gamma irradiation (data not 
shown), resulting in LQ model fit (Pearson R2 = 0.99) 
with α= 0.13 ± 0.02 /Gy, β = 0.025 ± 0.005 /Gy2 (α/β = 
5.5 Gy). Doubling time was estimated by fitting an 
exponential growth expression into PC-3 tumor 
growth curve in our model. Tumor control as a func-
tion of absorbed dose D over time T was expressed by 
Poisson statistics expressing the probability for sur-
vival S of 1 or more clonogenic cells from the original 
number of clonogenic cells Nclonogens by: 
𝑇𝑇𝑇𝑇𝑇𝑇 = exp (−𝑁𝑁𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑆𝑆(𝐷𝐷)), with the survival 
𝑆𝑆(𝐷𝐷,𝑇𝑇) = 𝑒𝑒𝑒𝑒𝑒𝑒 �−𝛼𝛼𝐷𝐷(𝑇𝑇)�1 + 𝐺𝐺(𝑇𝑇)𝛼𝛼
𝛽𝛽�
× 𝐷𝐷(𝑇𝑇)
𝑁𝑁
� + 𝛾𝛾𝑇𝑇� 
with γ the tumor growth constant and N the number 
of therapy cycles used. 
The dose prolongation factor G(T) can be ap-
proximated by the value integrated to infinity for 
single exponential dose build-up with effective 
half-life Teff: 𝐺𝐺(∞)  =  𝑇𝑇𝜇𝜇
𝑇𝑇𝜇𝜇+𝑇𝑇𝑒𝑒𝑒𝑒𝑒𝑒
    [24]. A Tumor Control 
Probability of > 90% was considered as being suc-
cessful.  
Small-animal PET 
Mice were injected iv with 2-8 MBq of 
68Ga-JMV4168 (200 pmol) in vehicle or vehicle con-
taining PA (300 µg). Mice were scanned 2 h after in-
jection, on a heated bed under isoflurane/O2 anesthe-
sia, in a small animal PET scanner (Inveon; Siemens 
Preclinical Solutions). PET emission scans were ac-
quired for 45 min, followed by a transmission scan 
(402 s). Scans were reconstructed using Inveon Ac-
quisition Workplace software (version 1.5; Siemens 
Preclinical Solutions), using a 3-dimensional or-
dered-subset expectation maximization/maximiza-
tion a posteriori algorithm with the following param-
eters: matrix, 256 x 256 x 161; pixel size, 0.40 x 0.40 x 
0.796 mm; and β-value, 1.0, with uniform variance 
and OPMAP. Images were rescaled to account for 
differences in injected dose.  
Therapy studies 
Mice received four ip injections in 2-days inter-
vals of either PBS, 177Lu-JMV4168 (50 MBq, 200 pmol) 
in vehicle or 177Lu-JMV4168 (50 MBq, 200 pmol) in 
vehicle containing PA (300 µg). To exclude a possible 
anti-tumor effect of radioprotectants, 
GRPR-antagonist or PA, a separate experiment was 
performed: mice received four ip injections of PBS, 
175Lu-JMV4168 in vehicle, or 175Lu-JMV4168 in vehicle 
containing PA (300 µg). Tumor size was followed 
twice weekly by caliper measurements, endpoints 
were tumor size exceeding 1.5 cm3, or survival of 94 
days after the first injection. 
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GRPR expression, histology and molecular 
characteristics 
In order to study the molecular response of tu-
mor cells to therapy, 2 mice of each group were sacri-
ficed 8 days after start of therapy, and tumor was 
dissected. At the endpoint of the experiment, tumor, 
kidney and pancreas from sacrificed animals of each 
group were dissected. For each organ half was frozen 
in liquid nitrogen and half was fixed in 10% neutral 
buffered formalin at 4°C. After fixation and routine 
dehydration, tissue samples were embedded in par-
affin. 
GRPR expression after radionuclide therapy 
treatment was assessed on frozen tumor sections (10 
µm) using autoradiography as described earlier [14]. 
In brief, frozen tissue sections were incubated with 
177Lu-JMV4168 (10-10 M) for 1 h in binding buffer con-
taining 1% w/v BSA. Unlabeled JMV4168 was used 
for blocking (10-6 M). Radioactivity was measured 
using a phosphor imager system (Cyclone, Packard 
A431201, PerkinElmer) and data obtained on different 
phosphor screens was normalized against a positive 
control slide (PC-295 xenograft tumor [25]).  
Histology was performed on paraffin-embedded 
kidney and pancreas sections (4 µm). Sections were 
stained with hematoxylin and eosin for microscopic 
examination using standard protocols. Immunofluo-
rescence and TUNEL staining were performed on 
paraffin-embedded tumor sections (4 µm) of mice 
sacrificed 8 days after therapy. 
For immunofluorescence staining, tumor sec-
tions were deparaffinized, rehydrated and target an-
tigen retrieval was performed using DAKO Antigen 
Retrieval buffer (pH 6.9) for 15 min at 100oC. Cells 
were permeabilized in PBS containing 0.1% Triton 
X-100 for 10 min and incubated in blocking buffer 
[PBS, 0.1% Triton X-100, 2% BSA]. Primary antibodies 
[anti-GEMININ (10802-1-AP, Proteintech Group, 
1/400 dilution), anti-53BP1 (NB100-304, Novus Bio-
logicals, dilution 1/1000), or anti-γH2AX (05-636, 
Merck-Millipore, dilution 1/500)] were diluted in 
blocking buffer and incubated for 90 min at room 
temperature (RT). Secondary antibodies (Alexa Fluor 
594 or 488, Life Technologies; dilution 1/1000) were 
diluted in blocking buffer and incubated for 60 min at 
RT.  
For apoptotic cell detection TUNEL staining was 
performed. Tumor sections were stained using an in 
situ cell death detection kit (11684795910, Roche). 
Briefly, cells were deparaffinized, rehydrated and 
incubated in PBS containing 0.5% Triton X-100 and 
proteinase K (20 μg/ml) for 15 min at RT. Cells were 
incubated in PBS containing 0.1% Triton X-100 and 
0.1% sodium citrate for 2 min on ice, followed by 
TUNEL labeling for 1 h at 37oC. Imaging was per-
formed using a DM4000 fluorescent microscope 
(Leica). 
γH2AX and 53BP1 imaging was performed using 
a TCS SP5 confocal microscope (Leica) and GEMININ 
imaging using a DM4000 fluorescent microscope 
(Leica).  
53BP1/γH2AX foci quantification was per-
formed with ImageJ software using automated 
threshold settings. GEMININ and TUNEL positive 
cells were counted manually and compared to the 
total number of DAPI-positive cells. Approximately 
1000 (53BP1/γH2AX) or 400 (GEMININ/TUNEL) 
DAPI-positive cells from different microscope fields 
per condition were evaluated.  
Statistical Analysis 
Statistical analysis was performed using 
GraphPad Prism version 5.01. Biodistribution data are 
represented as the mean %ID/g ± SD, with group 
sizes of 3-4 mice. Statistical analysis of biodistribution 
data was performed using a 2-way ANOVA with a 
Tukey’s multiple comparisons test, and the level of 
significance was set at P < 0.05.  
Mean tumor size with 95% confidence inter-
val were displayed for the period that all mice of one 
group were still in the experiments. Mice were sacri-
ficed when tumor exceeded 1.5 cm3, causing the mean 
size to drop, which made the comparison of the 
means not fair after that period. Survival analysis is 
displayed up to day 94, corresponding to a maximum 
follow up time. 
Statistical analysis of mean tumor size of all 
groups was performed up to day 24, when all animals 
were still in the experiment. A 2-way ANOVA with 
repeated measures was used to compare the three 
groups, with a Tukey’s multiple comparison test. 
Tumor size of the two treated groups was compared 
up to day 66, with a two-tailed paired t-test. Statistical 
analysis of survival data was performed using a 
Mantel-Cox Chi square test, with a level of signifi-
cance set at P < 0.05, corrected to 0.0167 for multiple 
comparisons. 
Tumor growth was analyzed by performing a 
non-linear regression fit of an exponential growth 
curve to the control group. The Aikake information 
criterion was used to determine whether the growth 
was exponential or showed a Gompertzian type of 
growth. The tumor growth data of the treated animals 
were fitted by an initial exponential growth curve till 
the onset time of shrinkage and an exponential re-
growth curve. Extrapolations of the growth curves for 
animals that were taken out of the experiment due to 
too large tumor sizes enabled establishment of a mean 
growth curve.  
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Results 
Radiolabeling of JMV4168 with 68Ga and 177Lu  
68Ga-JMV4168 was obtained with a specific ac-
tivity of 50 MBq/nmol. 177Lu-JMV4168 could be ob-
tained with a specific activity of up to 125 MBq/nmol 
using carrier added 177Lu/176Lu and 250 MBq/nmol 
using n.c.a. 177Lu. Labeling efficiency for 
68Ga-JMV4168 and 177Lu-JMV4168 exceeded 97% as 
determined by iTLC. Radiopeptides were not purified 
and radiochemical purity of preparations used in in 
vivo experiments exceeded 96% for 68Ga-JMV4168 and 
94% for 177Lu-JMV4168, as determined by RP-HPLC. 
An excess of EDTA/DTPA was added to complex free 
68Ga/177Lu and limit accumulation in bone. Protection 
of 177Lu-JMV4168 with radioprotectants (methionine, 
gentisic acid and ascorbic acid) was required to pre-
serve the peptide from radiolysis [26]. Radioprotect-
ants were added in the labeling reaction, as well as in 
the formulation for mouse injection. Radio-HPLC 
elution profiles of 68Ga- and 177Lu-JMV4168 are shown 
in Figure 2. 68Ga-JMV4168 and 177Lu-JMV4168 had 
retention times of 9.99 min and 12.57 min, respec-
tively.  
 
 
Figure 2. Radio-HPLC chromatograms of 68Ga-JMV4168 (A) and 177Lu-JMV4168 (B). 
 
PA stabilizes 177Lu-JMV4168 in murine pe-
ripheral blood 
In vivo stability studies resulted in 48% intact 
177Lu-JMV4168 in peripheral blood after 15 min, and 
an increase to 84% intact radiopeptide upon 
co-injection of PA.  
PA enhances tumor uptake of 68Ga- and 
177Lu-JMV4168 in PC-3 xenograft mice 
The results of the biodistribution studies of 68Ga- 
and 177Lu-JMV4168 are summarized in Figure 3. Bio-
distribution patterns of 68Ga- and 177Lu-JMV4168 at 1 
h after injection were comparable (p > 0.05 for all or-
gans). Tumor uptake (in %ID/g ± SD) at 1 h after iv 
injection increased from 9.9 ± 1.3 to 19.1 ± 2.6 
(68Ga-JMV4168, p < 0.0001) and from 9.0 ± 3.9 to 17.2 ± 
1.7 (177Lu-JMV4168, p < 0.0001) upon co-injection of 
PA. Uptake in the GRPR-positive pancreas was in-
creased at 1 h after iv injection for 68Ga-JMV4168 (p < 
0.0001), but not for 177Lu-JMV4168, upon co-injection 
of PA. No significant increase in uptake in non-target 
tissue was observed, resulting in high tu-
mor-to-background ratios. A 3-fold decrease in pan-
creatic uptake was observed for 68Ga-JMV4168 from 1 
h to 2 h after injection, while tumor uptake remained 
stable, leading to increased tumor/pancreas ratio over 
time. Biodistribution patterns of 177Lu-JMV4168 after 
iv or ip injection were fairly comparable. Increased 
uptake in pancreas was observed at 1 h after ip injec-
tion in comparison with iv injection (p < 0.0001), but 
no differences were observed at later time points. 
Tumor uptake values (in %ID/g ± SD) at 1 h, 4 h, and 
24 h after injection were 9.0 ± 3.9, 8.3 ± 1.7, and 4.2 ± 
1.0 after iv, versus 8.9 ± 2.4, 7.2 ± 2.1, and 4.5 ± 0.7 after 
ip injection, respectively. Tumor uptake at 4 h after 
injection increased to 12.9 ± 3.5 (iv), and 14.5 ± 3.7 (ip) 
upon co-administration of PA.  
Dosimetry of 177Lu-JMV4168 in PC-3 xenograft 
mice 
Single-exponential curves could be fitted to the 
biodistribution data; the tumor showed comparable 
clearance half-lives for the two types of injection (20.8 
± 8.5 h (iv) and 24.4 ± 8.3 h (ip)). Estimated absorbed 
radiation doses (in Gy) from 50 MBq 177Lu-JMV4168 in 
tumor, kidneys and pancreas were 10, 3.5, 2.5 Gy, and 
11, 7.3, 4.4 Gy after iv and ip injections, respectively. 
Absorbed doses for tumor, kidneys and pancreas for 
177Lu-JMV4168 with PA were 16, 3.7, 3.1 and 20, 7.6, 
4.8 Gy after iv and ip injections, respectively, assum-
ing equivalent clearance from 4 to 24 h as without PA. 
No significant differences were observed for absorbed 
radiation doses of normal organs for 177Lu-JMV4168 
and 177Lu-JMV4168 with PA. 
Based on the absorbed doses in PC-3 tumors, it 
was predicted that a single ip dose of 367 MBq (81 Gy) 
177Lu-JMV4168 would have a 95% probability to elicit 
full tumor control. However, a maximum of 50 MBq 
(200 pmol) could be administered per injection (spe-
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cific activity of 250 MBq/nmol). For 177Lu-JMV4168 
alone, 8 cycles of therapy (8 x 50 MBq, ip) with 2-days 
intervals would be needed to reach 98% TCP. Upon 
co-administration of 177Lu-JMV4168 and PA, 4 cycles 
of therapy (4 x 50 MBq, ip) with 2-days intervals 
would be needed to reach 93% TCP (Figure 4).  
 
 
Figure 3. Effect of phosphoramidon (PA) on the biodistribution of 68Ga-JMV4168 (200 pmol, 1 MBq) administered intravenously (iv) at 1 h and 2 h after injection (A) and 
177Lu-JMV4168 (200 pmol, 0.7 MBq) administered intravenously (B) or intraperitoneally (C) at 1 h, 4 h and 24 h after injection (n=3-4 per group). Biodistribution of 68Ga-JMV4168 
and 177Lu-JMV4168 at 1 h after injection were comparable. Tumor uptake of 177Lu-JMV4168 injected intraperitoneal and intravenously were comparable. Tumor uptake and 
tumor-to-background ratios were increased in the presence of PA. 
 
Figure 4. Theoretical survival curve of clonogenic cells in PC-3 xenograft (200 mg, 2 x 106 clonogenic cells at the start) after therapy with 4 injections (2-days intervals) of 50 
MBq of 177Lu-JMV4168 (4 x 11 Gy) and 177Lu-JMV4168 + phosphoramidon (4 x 20 Gy) (A). Tumor control probability (TCP) curve for the therapy with phosphoramidon is shown, 
reaching a 93% TCP after 9 days (B). 
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PA enhances sensitivity of small-animal PET 
imaging of 68Ga-JMV4168 in PC-3 xenograft 
mice 
PET images obtained at 2 h after iv injection of 
68Ga-JMV4168 are presented in Figure 5, showing 
clear, high-contrast visualization of PC-3 tumors. 
Visualization of PC-3 tumors was substantially im-
proved by co-injection of PA, as shown by the in-
creased signal intensity in the tumors.  
 
 
Figure 5. PET images of duplicate mice bearing subcutaneous PC-3 xenografts near 
the shoulder (pink arrow) injected with 68Ga-JMV4168 (A), or 68Ga-JMV4168 with 
phosphoramidon (B) at 2 h after injection, illustrating the higher tumor uptake in the 
presence of phosphoramidon. Excretion of the radiolabeled peptide in the bladder 
(white arrow) can be observed. Scale bar; 0 to 105 kBq/mL. 
 
PA augments therapeutic efficacy of 
177Lu-JMV4168 in PC-3 xenograft mice 
Therapy studies were conducted in PC-3 tu-
mor-bearing mice receiving four cycles of PBS, 
177Lu-JMV4168, or 177Lu-JMV4168 plus PA (Figures 6 
and 7). The 177Lu-JMV4168-treated mice showed sig-
nificant reduction in tumor size as compared to con-
trol (PBS) mice. At day 24 after start of therapy, mean 
tumor volumes (in mm3 ±SD) were 1181 ± 402, 146 ± 
35 and 145 ± 45 for PBS, 177Lu-JMV4168 and 
177Lu-JMV4168 plus PA, respectively. Tumor re-
growth was observed for both treated groups, with 
mean tumor volumes (in mm3 ± SD) of 770 ± 456 and 
381 ± 264 at day 66 for 177Lu-JMV4168 and 
177Lu-JMV4168 plus PA, respectively. Consequently, 
mice in both treated groups had an increased survival 
as compared to the control group (P < 0.0001) and 
mice treated with 177Lu-JMV4168 plus PA had an in-
creased survival as compared to mice treated with 
177Lu-JMV4168 alone (P = 0.0157). Median survival 
increased from 35 to 79 days upon treatment with 
177Lu-JMV4168, whereas the median survival in mice 
treated with 177Lu-JMV4168 plus PA was > 94 days, 
which was the endpoint of the experiment. Animal 
body weight remained stable during the course of the 
experiment and no apparent toxicity was observed 
(Figure 7).  
No significant differences in tumor growth and 
survival were observed for the groups treated with 
PBS, 175Lu-JMV4168 or 175Lu-JMV4168 plus PA, 
showing that vehicle, 175Lu-JMV4168 and PA had no 
effect on tumor growth (Figure 6).  
177Lu-JMV4168 radionuclide therapy results in 
DNA damage, apoptosis and decreased pro-
liferation and does not affect GRPR expression 
of PC-3 tumors 
Histological analysis of tumors, kidneys and 
pancreas dissected at the endpoint of the experiment 
showed overall healthy tissue, with some necrotic 
areas in the tumors (data not shown). Staining of mo-
lecular characteristics (DNA damage, replication, 
apoptosis and GRPR expression) of tumors from mice 
sacrificed 8 days after the last injection is presented in 
Figures 8, 9 and Figure 10.  
Tumors from the groups treated with 
177Lu-JMV4168 and 177Lu-JMV4168 plus PA showed 
an increased number of DNA double strand breaks 
(DSBs) as shown by phosphorylated histone 2AX 
(γH2AX) and p53-binding protein 1 (53BP1) foci for-
mation in the tumor cell nuclei. Co-injection with PA 
increased the amount of produced DSBs. Further-
more, decreased numbers of cells expressing 
GEMININ (replicating cells) and increased numbers 
of TUNEL-positive cells (apoptotic cells) were ob-
served after 177Lu-JMV4168 treatment. GRPR binding 
of 177Lu-JMV4168 on frozen tumor sections was pre-
served in PC-3 tumors from all groups. 
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Figure 6. Effect of phosphoramidon (PA) on therapeutic efficacy of 177Lu-JMV4168 to treat subcutaneous PC-3 tumors. Mice were treated with four injections of 177Lu-JMV4168 
(50 MBq, 200 pmol, n=12 per group) or 175Lu-JMV4168 (200 pmol, n=7 per group) on days 0, 2, 4 and 6, with or without PA. Mean tumor volume with 95% confidence interval 
(A, C) are displayed for the duration that no data point was missing. Kaplan-Meier survival curves (B, D) are displayed for the event of tumor volume exceeding 1500 mm3. All 
growth curves of the control mice could be fitted by an exponential growth curve, none should evidence for Gompertzian type of growth. The mean tumor volume doubling time 
was 11.2 ± 1.2 days. Regrowth of tumors in the treated animals was found after a kick-off time of 32 ± 4 days (177Lu-JMV4168) and 35 ± 6 days (177Lu-JMV4168 + PA) and showed 
comparable regrowth doubling times to the initial and control growth curves. No significant differences in tumor growth and survival were observed for the groups treated with 
PBS, 175Lu-JMV4168 or 175Lu-JMV4168 with PA. 
 
Figure 7. Therapeutic efficacy of 177Lu-JMV4168 to treat subcutaneous PC-3 tumors. Tumor size (A) and weight (B) follow up of mice treated with four injections of 
177Lu-JMV4168 (50 MBq, 200 pmol) on days 0, 2, 4 and 6, with or without PA (n=12 per group). 
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Figure 8. Representative pictures of 53BP1 and γH2AX staining (A), GEMININ staining (B) and TUNEL assay (C) on PC-3 paraffin-embedded tissues, 8 days after radionuclide 
therapy (control, 177Lu-JMV4168 and 177Lu-JMV4168 with phosphoramidon (PA)). Scale bar = 15 μm. 
 
Discussion 
In the search for an improved personalized can-
cer management, the field of theranostics is emerging, 
applying imaging diagnostics into the choice of the 
most suitable therapy for each patient. Bombesin an-
alogs have been widely used for molecular imaging 
[27] and radionuclide therapy [28-30] of PCa. The field 
was initially focused on bombesin agonists until a 
change in paradigm was introduced with somatosta-
tin receptor (SSTr) antagonists, which despite their 
poor internalization rate have shown more favorable 
pharmacokinetics and higher tumor uptake than ag-
onists [31-33]. Similarly to SSTr antagonists, GRPR 
antagonists have shown superior tumor-targeting and 
pharmacokinetic properties as compared to agonists 
[11], with promising characteristics for imaging [3, 4] 
and therapeutic applications [34]. Moreover, the use 
 Theranostics 2016, Vol. 6, Issue 1 
 
http://www.thno.org 
114 
of GRPR antagonists should prevent side effects such 
as nausea, hot flush and sweating, which were pre-
viously observed in patients injected with a bombesin 
receptor agonist [12, 13]. In a previous study per-
formed by Dumont et al. [34] the potential of 
GRPR-targeted radionuclide therapy using a GRPR 
antagonist, 177Lu-RM2, and enhancement of thera-
peutic efficacy in combination with rapamycin were 
reported. GRPR-antagonists can be used as 
theranostic agents for PCa, but rapid in vivo degrada-
tion of these peptides by proteolytic enzymes may 
strongly hamper their targeting properties. Strategies 
to improve in vivo stability of radiolabeled peptides 
include various structural modifications, such as key 
amino acid substitutions, reduction/methylation of 
biodegradable bonds or cyclization, but these modi-
fications can cause undesired changes in pharmaco-
kinetics and/or impair receptor affinity [35-37]. The 
proteolytic enzyme NEP, which is abundant in the 
human body [38-40], cleaves peptides on the amino 
side of hydrophobic amino acids, thereby inactivating 
a broad range of neuropeptides, including 
bombesin-like peptides [15-17]. Recently we have 
shown that co-injection of the NEP inhibitor PA [41] 
could stabilize radiolabeled bombesin, minigastrin 
and somatostatin analogs in vivo, leading to enhanced 
tumor uptake [18, 42]. 
In this preclinical study, we have brought this in 
vivo stabilization concept to the next level, showing 
that co-injection of PA can contribute to an impressive 
enhancement in diagnostic sensitivity and therapeutic 
efficacy of a GRPR-targeted theranostic agent. We 
labeled the GRPR-antagonist JMV4168 with 68Ga for 
PET imaging and 177Lu for radionuclide therapy. All 
in vivo studies were performed with 200 pmol 
JMV4168, which appeared to be the optimal peptide 
dose in previous experiments (data not shown). The 
dose of 300 µg of PA was chosen based on previous 
experience [18]. Optimization of PA-dose for this 
68Ga-/177Lu-JMV4168 theranostic pair has not been 
conducted, as the major purpose of the present study 
has been to show the PA-effect in therapy in a quali-
tative “proof-of-principle” approach. 177Lu-labeling of 
JMV4168 with very high specific activities (250 
MBq/nmol) could be achieved using n.c.a. 177Lu. In 
vivo stability studies in mice showed excellent stabi-
lization of 177Lu-JMV4168 in peripheral blood upon 
co-injection of PA. 
 
 
Figure 9. Representative pictures of γH2AX and 53BP1 foci staining on PC-3 paraffin-embedded tissues 8 days after radionuclide therapy (control, 177Lu-JMV4168 and 
177Lu-JMV4168 with phosphoramidon (PA)). Scale bar = 3 μm. 
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Figure 10. Quantification of number of 53BP1 foci per nucleus (A), and number of cells scored positive for GEMININ (B) or TUNEL (C) on PC-3 paraffin-embedded tissue, 8 
days after radionuclide therapy. (D) GRPR binding of 177Lu-JMV4168 on PC-3 frozen sections after radionuclide therapy (endpoint). 
 
Biodistribution of 68Ga-JMV4168 and 
177Lu-JMV4168 was compared in nude mice with sc 
PC-3 human tumors. The similar biodistribution pat-
terns of 68Ga-JMV4168 and 177Lu-JMV4168 at 1 h after 
injection indicate that 68Ga-JMV4168 could serve as a 
surrogate to 177Lu-JMV4168 for PET imaging-based 
patient selection and follow up of therapy outcome. 
Tumor uptake of 177Lu-JMV4168 was similar to tumor 
uptake of 177Lu-RM2 reported by Dumont et al. [34]. 
Tumor uptake of 68Ga- and 177Lu-JMV4168 was dou-
bled by co-injection of PA, while most non-target 
background organs and blood levels were not en-
hanced, leading to higher tumor-to-background rati-
os. Although uptake of 68Ga-JMV4168 in the 
GRPR-positive pancreas was also increased by 
co-injection of PA at 1 h after injection, rapid washout 
from the pancreas was observed between 1 h and 2 h 
after injection, in agreement with previous findings 
[14]. These increased tumor uptake values were visu-
alized on PET images acquired at 2 h after injection, 
showing higher signal intensity in the PC-3 tumors in 
mice that received co-injection of PA, with unaltered 
low intensity in the pancreas area. This suggests that 
PA could increase sensitivity of detection of small PCa 
lesions in patients.  
Dosimetry of 177Lu-JMV4168 was evaluated to 
predict therapy outcome and to optimize the design 
of therapy studies. Administration of 177Lu-JMV4168 
via the ip route was preferred to reduce injection 
failure rate and radiation exposure rate to researchers. 
Based on dosimetry calculations, therapy studies were 
conducted in nude mice with sc PC-3 tumors with 4 
cycles of 50 MBq of 177Lu-JMV4168 (ip) with 2-days 
intervals. This schedule resulted in an impressive de-
crease and stabilization of tumor size as compared to 
that in untreated mice. More strikingly, 
co-administration of PA to 177Lu-JMV4168 resulted in 
increased survival. Several reports have suggested a 
role of NEP in PCa progression [43-45]. Minimal effect 
of NEP inhibition on PC-3 tumor growth was ex-
pected, as previous studies have shown lack of NEP 
expression in PC-3 cells [45-47]. Consistently, our re-
sults revealed no effect of PA on PC-3 xenograft tu-
mor growth. However, we would recommend testing 
the effect of PA for each new model being investi-
gated in similar studies.  
In order to confirm the efficacy of radionuclide 
therapy at the molecular level, we evaluated the oc-
currence of DSBs, proliferation and apoptosis in PC-3 
tumors. The β-particles emitted by the radionuclide 
177Lu induce several types of DNA damage, among 
which DSBs are the most genotoxic; because unre-
paired DSBs can trigger cell cycle arrest, cell death 
(apoptosis) or chromosomal aberrations. DSBs pro-
duced by ionization radiation activate a cascade of 
events, including protein modifications (such as 
γH2AX) and accumulation of several DNA damage 
response proteins (one of these proteins is the key 
DSB repair regulator 53BP1) [48]. After DSB induc-
tion, γH2AX and 53BP1 can be visualized as nuclear 
foci at the DSBs providing a measure of DSB induc-
tion. 
PC-3 tumors dissected 8 days after the last ther-
apeutic injection revealed increased number of DSBs, 
as shown by the increase in γH2AX and 53BP1 foci for 
the groups treated with 177Lu-JMV4168 and 
177Lu-JMV4168 with PA. Furthermore, an increased 
production of DSBs was observed in mice that re-
ceived co-administration of PA, which was consistent 
with the higher 177Lu-JMV4168 tumor uptake and the 
improved therapeutic outcome.  
In both treated groups, we also observed de-
creased replication, as shown by the reduction in the 
number of cell expressing the cell cycle marker 
GEMININ. In line with these results, TUNEL staining 
showed an increased level of apoptosis after treat-
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ment. No significant difference in the number of 
GEMININ- and TUNEL-positive cells was observed 
between both treated groups, unlike DNA damage 
data. This could be due to different kinetics of DNA 
damage repair, proliferation and apoptosis.  
Altogether, these parameters confirm tissue 
damage and subsequent tumor volume reduction 
induced by the radionuclide treatment with 
177Lu-JMV4168. Importantly, GRPR expression was 
maintained on re-growing PC-3 tumors after radio-
nuclide therapy, excluding the possibility of a selec-
tion of GRPR-negative cells, and allowing repeated 
treatment with the same probe.  
In conclusion, this study highlights the potential 
of the GRPR-targeted peptide-based theranostic ap-
proach for imaging and treatment of PCa. Besides 
treatment of PCa patients, this approach could be ap-
plied to a wider range of GRPR-expressing tumors, 
such as breast tumors [49]. Moreover, it shows how 
co-injection of the NEP inhibitor PA can greatly en-
hance diagnostic sensitivity and therapeutic efficacy. 
We believe that this strategy may contribute to an 
improved management of PCa patients and warrants 
translation into a clinical setting. For that purpose, 
clinically certified NEP inhibitors should be preferred 
to facilitate translation. 
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